Arcus Biosciences reports Q2 net loss of $76M, cash $805M; appoints Nicole Lambert to board

Arcus Biosciences, Inc.

Net loss $76.0M for Q2 2021 vs $45.1M in Q2 2020; six-month net loss $148.6M.
Collaboration revenue $9.5M in Q2 2021 vs $1.8M; R&D expenses $68.8M (up from $35.7M).
Cash and investments $805.1M as of June 30, 2021 vs $735.1M at Dec 31, 2020; funded at least through 2023.
Appointed Nicole Lambert to Board of Directors, President of Myriad Genetic Laboratories.
Pipeline: HIF-2α inhibitor AB521 enters clinic in Q4 2021; domvanalimab combination data promising; randomized ARC-8 enrollment to complete by year-end.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicole Lambert

Director

RCUS · Arcus Biosciences, Inc.

Effective: 2021-08-03
Filed: August 5, 2021, 7:59 PM ET

On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nicole Lambert was appointed as Director at Arcus Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.

View on SEC.gov

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-041591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.